AI-enabled drug discovery company MultiOmic Health has closed a 拢5m seed funding extension round.
The round was over subscribed and led by London-based聽Hoxton Ventures, with participation from聽Ada Ventures, MMC Ventures and Verve Ventures.
Since beginning operations in May 2021, MultiOmic has raised nearly 拢7m, including an earlier round led by San Francisco-based Fifty Years.
The latest investment will be used to demonstrate proof-of-concept for MultiOmic鈥檚 MOHSAIC platform in diabetic kidney disease.
It鈥檚 estimate that up to 40 per cent of diabetics eventually develop chronic kidney disease and account an estimated $300bn (拢238bn) annually in global healthcare costs.
Robert Thong, MultiOmic鈥檚 co-founder and CEO, said: 鈥淓xisting treatments for metabolic syndrome-related conditions merely reduce risk or delay onset of serious consequences such as heart attack, stroke, kidney failure, blindness, nerve damage, foot amputation, liver failure and premature death.
鈥淧atients鈥� disease journeys exhibit immense heterogeneity, reflecting potentially hundreds of different disease variants that result not only from inherited genetics, but also diet, lifestyle and other environmental factors.
鈥淯nlike cancer however, there are no existing precision medicines to tackle the specific molecular-level drivers of each metabolic syndrome disease variant.
Flight Fund invests 拢2.1m into personalised nutrition firm ZOE
鈥淲e will address this huge unmet medical need by systematically discovering, at scale, unique treatment concepts for these different disease variants.
鈥淥ur human-centric platform originates therapeutics from high fidelity patient data, reversing the traditional drug discovery models that initiate treatments from test tube and animal experiments.
鈥淲e are going from bedside to lab bench, rather than from lab bench to bedside!鈥�
Metabolic syndrome聽is the medical term for a combination of diabetes, high blood pressure (hypertension) and obesity.
Rob Kniaz, partner at Hoxton Ventures, said: 鈥淲e are very excited to be partnering with Robert and the team at MultiOmic.
鈥淢etabolic syndrome and its resultant medical conditions are the most significant cause of death globally, and this is forecast to increase since Covid survivors are at a much higher of being affected.
鈥淲e couldn鈥檛 be more bullish about the transformational impact that innovations at the intersection of tech and bio are having on patients 鈥� we see tremendous potential in the space.
鈥淰ia our investment in MultiOmic, we see a very exciting opportunity to use technology to address an area of high unmet need where conventional approaches have historically failed.鈥�
Charlotte Barttelot, principal at MMC Ventures, said: 鈥淎fter closely analysing the evolving next generation of AI drug discovery platforms, we were impressed by MultiOmic鈥檚 approach. Building a computational systems biology engine founded on a deep integrated omics dataset is the only way to address the knowledge gap in metabolic diseases. Robert has assembled a top tier multi-disciplinary team to address this complex data problem.鈥�